Evidence map›Paper›PMID 38129928›Full record

ArticleJournal of nanobiotechnology2023

Carbon dot nanozymes as free radicals scavengers for the management of hepatic ischemia-reperfusion injury by regulating the liver inflammatory network and inhibiting apoptosis.

Haoge Geng, Jiayu Chen, Kangsheng Tu, Hang Tuo, Qingsong Wu, Jinhui Guo, Qingwei Zhu, Zhe Zhang, Yujie Zhang, Dongsheng Huang and 2 more

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. The Protective Effect of N, Ce-doped Carbon Dots Against HApplied biochemistry and biotechnology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Design of nanoMaterials today. Bio · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Preparation and Application of Carbon Dots Nanozymes.Antioxidants (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Haoge Geng *Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.
Jiayu Chen *Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
Kangsheng TuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China. tks0912@foxmail.com.
Hang TuoDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
Qingsong WuThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China.
Jinhui GuoQingdao Medical College, Qingdao University, Qingdao, Shandong, 266071, China.
Qingwei ZhuQingdao Medical College, Qingdao University, Qingdao, Shandong, 266071, China.
Zhe ZhangThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China.
Yujie ZhangSchool of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
Dongsheng HuangLaboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China. dshuang@hmc.edu.cn.
Mingzhen ZhangSchool of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China. mzhang21@xjtu.edu.cn.ORCID http://orcid.org/0000-0002-4686-6526
Qiuran XuLaboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China. windway626@sina.com.ORCID http://orcid.org/0000-0003-2171-9279
First Affiliated Hospital of Xi'an Jiaotong University · CNZhejiang Provincial People's Hospital · CNQingdao University · CNXi'an Jiaotong University · CNZhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatic ischemia-reperfusion injury (HIRI) is a pathophysiological process during liver transplantation, characterized by insufficient oxygen supply and subsequent restoration of blood flow leading to an overproduction of reactive oxygen species (ROS), which in turn activates the inflammatory response and leads to cellular damage. Therefore, reducing excess ROS production in the hepatic microenvironment would provide an effective way to mitigate oxidative stress injury and apoptosis during HIRI. Nanozymes with outstanding free radical scavenging activities have aroused great interest and enthusiasm in oxidative stress treatment.

resultsWe previously demonstrated that carbon-dots (C-dots) nanozymes with SOD-like activity could serve as free radicals scavengers. Herein, we proposed that C-dots could protect the liver from ROS-mediated inflammatory responses and apoptosis in HIRI, thereby improving the therapeutic effect. We demonstrated that C-dots with anti-oxidative stress and anti-inflammatory properties improved the survival of L-02 cells under H

conclusionsWith negligible systemic toxicity, our findings substantiate the potential of C-dots as a therapeutic approach for HIRI, thereby offering a promising intervention strategy for clinical implementation.

Indexed as

Hydrogen PeroxideReperfusion InjuryAnimalsApoptosisLiverReactive Oxygen SpeciesHydrogen PeroxideReactive Oxygen SpeciesC-dots nanozymesHepatic ischemia-reperfusion injury (HIRI)Inflammatory networkOxidative stressReactive oxygen species (ROS)

Identifiers

PMID38129928
PMCPMC10734184
OpenAlexW4390054608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.